全国服务咨询热线：
18438616290
18438616290
产品分类
Product Category详细介绍
| 品牌 | absin | CAS | 1188-38-1 |
|---|---|---|---|
| 分子式 | C6H10N2O5 | 纯度 | ＞98% |
| 分子量 | 190.15 | 货号 | abs47027285 |
| 规格 | 5mg | 供货周期 | 现货 |
| 主要用途 | used for the treatment of hyperammonaemi | 应用领域 | 化工,生物产业,农林牧渔,制药/生物制药,综合 |
Carglumic Acid 1188-38-1
| 产品描述 | |
| 描述 | Carglumic acid is an orphan drug used for the treatment of hyperammonaemia in patients with N-acetylglutamate synthase deficiency. This rare genetic disorder results in elevated blood levels of ammonia, which can eventually cross the blood-brain barrier and cause neurologic problems, cerebral edema, coma, and death. Carglumic acid was approved by the U.S. Food and Drug Administration (FDA) on 18 March 2010. |
| 纯度 | ＞98% |
| 储存/保存方法 | Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution. |
| 基本信息 | |
| 别名 | 卡谷氨suan；卡哥鲁酸；N-氨基甲酰-L-谷氨suan；N-Carbamyl-L-glutamic acid |
| 可溶性/溶解性 | DMSO ：38 mg/mL (199.84 mM) Water ：3 mg/mL (15.78 mM; Need ultrasonic and warming) |
| 生物活性 | |
| 靶点 | CPS1 |
| In vitro(体外研究) | Carglumic acid suppresses cell viability in the pancreatic ductal adenocarcinoma cell lines, triple-negative breast cancer cell lines, hepatoma cell lines, and human non-small cell lung carcinoma cell lines in a dose-dependent manner. The 50% inhibitory concentration (IC50) of Carglumic acid against those cell lines is between 5 and 7.5 mM. The results show that Carglumic acid does not induce complete cell cycle arrest. Instead, there are more sub-G1 cells among Carglumic acid-treated AsPC1 and MDA-MB-231 cells than among untreated cells. In AsPC1 and HPDE-E6E7 cells, the IC50s of Carglumic acid are 5 mM and over 10 mM, respectively . In MDA-MB-231 and MCF-12A cells, the IC50s of Carglumic acid are 5 mM and 6 mM, respectively. |
| In vivo(体内研究) | The results show that Carglumic acid, but not the vehicle control, markedly inhibits tumor growth. In the orthotopic pancreatic cancer model, tumor growth inhibition by Carglumic acid on day 21 is 80% (P<0.01). In the orthotopic triple-negative breast cancer model, tumor growth inhibition by Carglumic acid on day 20 is 82% (P<0.01). These results indicate that Carglumic acid suppresses tumor growth in pancreatic cancer and triple-negative breast cancer. On day 20, mean tumor growth inhibition in orally and intravenously treated mice is 55% and 93%, respectively, relative to untreated mice (P<0.01). |
| 参考文献 | |
| 参考文献 |
|
| 研究领域 | |
| 研究领域 | MetabolismPathways and ProcessesMetabolic signaling pathwaysAmino acid metabolism MetabolismPathways and ProcessesMitochondrial MetabolismMitochondrial markers Signal TransductionMetabolismAmino Acids Signal TransductionMetabolismMitochondrial Tags & Cell MarkersSubcellular MarkersOrganellesMitochondria Drug DiscoverySmall Molecule DrugLead Compound Discovery |
产品咨询
地址：上海市浦东新区新浩路58号申江科创园18栋
邮箱：lanwu@univ-bio.com
传真：